Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | VNN1 | O95497 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ASPH | Q12797 | 1/20 | 0.46 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.46 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | ACP1 | P24666 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16982690 | 0.83 | KDM4E (0.56) | KDM4EHTTMAPTLMNATSHR | |
| SCHEMBL21600856 | 0.82 | KDM4E (0.49) | PDE5AKDM4EMAPTTSHRMEN1 | |
| SCHEMBL30380072 | 0.82 | KDM4E (0.49) | PDE5AKDM4EMAPTTSHRMEN1 | |
| SCHEMBL21722982 | 0.79 | LMNA (0.51) | VNN1KDM4EASPHRIOX2KDM8 | |
| SCHEMBL30581495 | 0.79 | LMNA (0.51) | VNN1KDM4EASPHRIOX2KDM8 | |
| SCHEMBL29079963 | 0.79 | KDM4E (0.46) | NPC1PDE5AVNN1KDM4EASPH | |
| SCHEMBL21600939 | 0.78 | CYP1A2 (0.48) | KDM4EASPHKDM8MAPTLMNA | |
| SCHEMBL30380185 | 0.78 | MAPT (0.48) | NPC1MAPTLMNAMEN1KMT2A | |
| SCHEMBL21600877 | 0.78 | MAPT (0.48) | NPC1MAPTLMNAMEN1KMT2A | |
| SCHEMBL30379700 | 0.78 | CYP1A2 (0.48) | KDM4EASPHKDM8MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999732-B2 | P2X3 receptor antagonists | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2024-06-04 | — | — | US | disclosed |
| CN-112584898-B | P2X 3 Receptor antagonists | 瑞蔻达蒂化学和制药工业股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20210246139-A1 | P2X3 RECEPTOR ANTAGONISTS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2021-08-12 | — | — | US | disclosed |
| EP-3820566-A1 | P2X3 RECEPTOR ANTAGONISTS | Recordati Industria Chimica E Farmaceutica SPA (IT) | 2021-05-19 | — | — | EP | disclosed |
| CN-112584898-A | P2X3Receptor antagonists | 瑞蔻达蒂化学和制药工业股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2020011921-A1 | P2X3 RECEPTOR ANTAGONISTS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246139-A1 | P2X3 RECEPTOR ANTAGONISTS | P2RX3, P2RX5, P2RX2 | NPC1 3911/4885PDE5A 371/4885VNN1 1583/4885 |
| US-11999732-B2 | P2X3 receptor antagonists | P2RX3, P2RX5, P2RX2 | NPC1 3911/4885PDE5A 371/4885VNN1 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.